PDCD1 and non-small cell lung carcinoma: When investigating an association between intratumoral neoantigen load and responsiveness to PD-1 blockade, McGranahan et al. found that a high clonal neoantigen burden in tumors of anti-PD-1 antibody-treated NSCLC patients is associated with improved clinical outcome [79].